What is StemRad?
StemRad is at the forefront of developing innovative radiation protection products, most notably its Radiation Shield technology. This groundbreaking system provides targeted shielding for vital organs, a critical advancement for professionals and civilians facing radiation risks. Their clientele spans diverse high-risk sectors including firefighters, military personnel, medical crews, astronauts, and the general public. StemRad's technology is built upon scientific breakthroughs designed to protect users while maintaining essential mobility during critical operations. The company's commitment to enhancing survival rates from high radiation doses and mitigating cancer risks from low-level exposures has garnered significant industry recognition.
How much funding has StemRad raised?
StemRad has raised a total of $6M across 1 funding round:
Series C
$6M
Series C (2017): $6M, investors not publicly disclosed
What's next for StemRad?
The recent major strategic investment in StemRad signals a strong validation of its technology and market potential. This capital infusion is expected to accelerate the company's growth trajectory, enabling further research and development, expansion into new markets, and scaling of production capabilities. StemRad's focus on critical safety solutions positions it for continued success in sectors where radiation protection is paramount. The company's ability to provide effective shielding without compromising mobility is a key differentiator, suggesting a future of broader adoption and impact in high-risk environments.
See full StemRad company page
